Use of bacillus Calmette–Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort

References

• Regionalt Cancercentrum (RCC). Nationellt kvalitetsregister för blåscancer, Rapport för diagnosår 2011. [In Swedish.]. Available from http://www.cancercentrum.se/Global/Diagnoser/blåscancer/rapporter/blasrapport2011.pdf.
   Google Scholar
• Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62–7.
   PubMed Web of Science ®Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639–53.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette–Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742–50.
   PubMed Web of Science ®Google Scholar
• International Union Against Cancer. Sobin LH, Gospodarowicz MK, Wittekind C. The TNM classification of malignant tumours. 7th ed. Available from http://www.uicc.org/resources/tnm.
   Google Scholar
• Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011;107:404–8.
   PubMed Web of Science ®Google Scholar
• Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105–8.
   PubMed Web of Science ®Google Scholar
• National Board of Health and Welfare, Stockholm, Sweden. Cause of Death Register. Available from http://www.socialstyrelsen.se/register/dodsorsaksregistret.
   Google Scholar
• Sabir EF, Holmäng S, Liedberg F, Ljungberg B, Malmström PU, Månsson W, et al. Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol 2013;47:483–90.
   PubMed Web of Science ®Google Scholar
• Gårdmark T, Bladström A, Hellsten S, Malmström PU. Members of the Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 2006;40:276–82.
   PubMed Web of Science ®Google Scholar
• Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, et al. Adjuvant intravesical bacillus Calmette–Guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:92–8.
   PubMedGoogle Scholar
• Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette–Guérin therapy. Urol Oncol 2008;26:137–40.
   PubMed Web of Science ®Google Scholar
• Yuge K, Kikuchi E, Matsumoto K, Takeda T, Miyajima A, Oya M. Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? Jpn J Clin Oncol 2011;41:565–70.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Van der Mejden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette–Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596–600.
   PubMed Web of Science ®Google Scholar
• Duchek M, Johansson R, Jahnson S, Mestad O, Hellström P, Hellsten S, et al. Members of the Urothelial Cancer Group of the Nordic Association of Urology. Bacillus Calmette–Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25–31.
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette–Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–72.
   PubMed Web of Science ®Google Scholar
• Regionalt Cancercentrum (RCC): National Guidelines for Cancer in the Urinary Bladder, Ureter, Urethra and Renal Pelvis (Nationellt Vårdprogram för Cancer I urinblåsa, urinledare, urinrör och njurbäcken) 2013. [In Swedish.]. Available from http://www.cancercentrum.se/Global/RCC%20Samverkan/Dokument/Vårdprogram/NatVP_cancer_urinvägarna_130523_final.pdf.
   Google Scholar
• Divrik RT, Sahin AF, Yildirim Ü, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010;58:185–90.
   PubMed Web of Science ®Google Scholar